Pharmaceutical manufacturers of Tranexamic acid

We specialize in premium Active Pharmaceutical Ingredients (APIs), Formulations, Innovative Drug Delivery Systems, and Specialty Chemicals using advanced technology with precision to adhere to global standards/specifications. Presently, we are recognized as one of the foremost global providers of Oncology/non-Oncology APIs, intermediates, and Formulations. Shilpa Medicare’s establishments have garnered significant regulatory endorsements from USFDA, EUGMP, TGA, PMDA, Cofepris, Anvisa, and KFDA, encompassing diverse regulatory approved manufacturing standards.

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

We are utilizing the world's top-level fermentation and synthesis technologies to supply domestic and overseas users with various fine chemical products centered on amino and nucleic acids for pharmaceuticals, nutritional supplements, and industrial use, as well as the derivatives of such acids. Through the rapid progress in genome analysis seen in recent years, we anticipate the development of new biotechnology processes and products from fermentation, a technology which humankind has been utilizing since time immemorial.

Daiichi Sankyo is an international pharmaceutical organization with its corporate roots in Japan. We offer pioneering products and services in over 20 nations across the globe. Leveraging over a century of scientific knowledge, our company taps into a rich history of creativity and a strong lineup of promising new medications to aid patients. Through the exceptional expertise and dedication of our 15,000 staff members worldwide, we develop inventive novel and generic medications, as well as fresh approaches to drug discovery and distribution. We are driven by a dedication to innovation and a deep concern for patients worldwide who require our medications.

Transo-Pharm, a fully authorized and accredited distributor, specializes in pharmaceutical components for the medical and veterinary sectors. It provides assistance to customers throughout the entire API life cycle, from product innovation to sales. Transo-Pharm acts as a sourcing and regulatory marketing representative for API producers. It assists customers in establishing DMFs and offers GMP advisory services. With a dedicated regulatory division, a storage facility, proprietary IPs for API procedures, and collaborations with research facilities, Transo-Pharm offers a broad array of services. It operates from its establishments in Shanghai, Hong Kong, Singapore, and the United States.

Ami Lifesciences, established in 2006, is one of the fastest growing Active Pharmaceutical Ingredient (API) manufacturing companies in India, meeting unmet patient needs in various therapeutic areas such as Cardiovascular, Anti-Diabetics, CNS, and Respiratory amongst other categories, produced From Manufacturing unit located in Vadodara, Gujarat. We are recognised as a reliable supplier of generic APIs and a trustworthy Contract Development & Manufacturing partner for generic, Big Pharma & innovator pharmaceutical companies worldwide. We are among the leading manufacturers of APIs, intermediates and registered Key Starting Materials offering quality products with highest quality compliance & integrity to over 60+ countries. We believe, unlocking early launch opportunities, being cost competitive by virtue of backward integration and offering complete supply chain assurance is key to enable our customers to succeed & sustain their products through the product life cycle over a period of time.

Established in 1980 by microbiologist Mr. M L N Sastry, Malladi Drugs & Pharmaceuticals Ltd quickly emerged as a pioneer in the production of ephedrine and pseudoephedrine salts. Today, it holds a prominent position as a manufacturer of APIs in the cough and cold segment, as well as in therapeutic segments such as antihistamines, anti-convulsants, anti-depressants, and anxiolytics (CNS). With a vast export network spanning approximately 60 countries, the company derives over 85% of its revenue from international markets. Malladi's manufacturing units have received approval from prominent regulatory bodies including the FDA, EDQM, KFDA, and TGA.

Rochem International, Inc. has been a prominent distributor of pharmaceutical, food, nutritional, and animal health ingredients since its establishment in 1994. It procures top-notch ingredients produced in China. With its headquarters in Hauppauge, New York, Rochem operates 16 global offices to meet its clients' requirements. The company's activities adhere to cGMP standards and have undergone audits by the USFDA and various multinational entities. Furthermore, it provides training and conducts audits for its partners to ensure FDA compliance for their technologies and systems.

The Asahi Kasei Group is a diversified manufacturer centered on chemistry, founded in 1922 with the purpose of "improving people's standard of living by supplying an abundance of the highest-quality daily necessities at the lowest prices." The history of the Asahi Kasei Group is rooted in Japan's first ammonia production by chemical synthesis, using hydroelectric power, which formed the basis for our synthetic chemicals and chemical fibers businesses. Since then, we have continued to proactively diversify and adapt our operating portfolio in accordance with changes in the economy, changes in society, and changes in the environment. We now contribute to life and living for people around the world through our operations in the three business sectors of Material consisting of fibers, chemicals, and electronics; Homes consisting of homes and construction materials; and Health Care consisting of pharmaceuticals, medical devices, and acute critical care. The products, technologies, and services of the Asahi Kasei Group can create new value that helps society overcome current challenges by contributing to a clean environment, to clean energy, and to longevity with health, comfort, and peace of mind. We will fulfill our Group Slogan of "Creating for Tomorrow" by leveraging the broad-ranging businesses and multifaceted human resources gained across our history of diversification to actively innovate through our products, technologies, and services.

Inabata France, a division of the Inabata Group, was established in 1990 to export chemical and medicinal products to Japan. It purchased Pharmasynthèse in 2006. Inabata-Pharmasynthèse provides an extensive range of services, including procurement, production, and innovation of raw materials for the pharmaceutical and beauty sectors. It delivers pharmaceutical and beauty components to Europe, Japan, and other regions worldwide. Its specialty lies in the manufacture of high-quality chemicals. Manufacturing is conducted at its versatile facility in St Pierre-Les-Elbeuf, France, ranging from pilot to commercial scales. The plant operates under GMP conditions.

Explore Good Pharmaceutical LLC is situated in Hefei Economic and Technology Development Zone. Our firm is a collaboration involving Chinese Hong Kong and Japan. At present, there are a total of 275 employees. Furthermore, we have constructed a versatile production facility, hydrogenation facility, refining-drying-packing facility, and bromination facility. In addition, we have set up a secure storage area for solid raw materials, liquid raw materials, finished products, and hazardous chemicals. We cordially invite your partnership and anticipate working together to forge an outstanding future jointly.

Zhejiang Bamboo Pharmaceuticals emerged in 2020 as a pioneering and eco-friendly producer of top-notch pharmaceutical API. Its expansive facility spans approximately 66,000m2, with a dedicated plant area covering 50,000 m2. The company specializes in gabapentin, benzocaine, pregabalin, tranexamic acid, levocarnitine, as well as a food additive: dimethyl dicarbonate. Moreover, each API is accompanied by US DMF, CEP certificate, and written confirmation, solidifying its commitment to quality and compliance. Zhejiang Bamboo Pharmaceuticals sets itself apart as a contemporary and regulatory organization, focusing on both API and formulation drug manufacturing. While the formulation drugs primarily target the domestic market, the company aspires to secure a prominent position as a major supplier for the Chinese '4 + 7' volume procurement program.

Novell Pharmaceutical Laboratories stands as a prominent and well-established pharmaceutical company in Indonesia. Our proficiency extends to serving the global market by providing finished products and contract manufacturing services under the buyer's brand name, coupled with competitive pricing and exemplary product quality. Our manufacturing facility is adept at producing various preparations including tablets, capsules, liquid, and sterile preparations. With approvals from the European Union authority, Australian TGA, Executive Board of Health Ministers' Council for GCC States, and South Africa - MCC, we ensure the reliability and safety of our products.

Yantai Valiant Fine Chemicals Co. Ltd. is among the limited public companies specializing in fine chemicals in China. The company is dedicated to the research, development, production, and distribution of fine chemical products, which encompass liquid crystal materials, pharmaceutical intermediates, and photoelectronic chemicals. Valiant's premises cover an expanse of 154,000.00 square meters, with the plant construction area occupying 39,000.00 square meters

Established in 2005, Coben Group was created and constructed in accordance with GMP standard covering a total area of 100,000 square meters. It is a part of ZJMI Group-Global Fortune 500, achieving the 270th position in 2018. Coben specializes in the research and production of APIs and intermediates for a variety of medications. Its primary products consist of Sofosbuvir, Tenofovir, Ticagrelor, Sacubitril, Voriconazole, Isavuconazole, and their respective intermediates.